Compare · ARGX vs GLUE
ARGX vs GLUE
Side-by-side comparison of argenx SE (ARGX) and Monte Rosa Therapeutics Inc. (GLUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and GLUE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.96B, about 30.3x GLUE ($1.75B).
- Over the past year, ARGX is up 50.5% and GLUE is up 337.6% - GLUE leads by 287.2 points.
- GLUE has been more active in the news (13 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for GLUE).
- Company
- argenx SE
- Monte Rosa Therapeutics Inc.
- Price
- $853.73-5.62%
- $20.70+10.87%
- Market cap
- $52.96B
- $1.75B
- 1M return
- +4.55%
- +9.70%
- 1Y return
- +50.48%
- +337.63%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 4
- 13
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest GLUE
- Chief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $57,000 worth of shares (3,000 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Director Behbahani Ali
- SEC Form 4 filed by Director Schiff Andrew N
- SEC Form 4 filed by Director Manning Anthony M.
- SEC Form 4 filed by Director Skvarka Jan
- SEC Form 4 filed by Director Siu Christine
- SEC Form 4 filed by Director Hughes Eric A
- SEC Form 4 filed by Director Blackwell Kimberly
- Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders